HMNC Brain Health Initiates Pioneering Precision Therapy Program in Mental Health
- Pioneering the first large-scale double-blind studies to test the combination of therapies and genetic companion diagnostics in the area of mental health
- Partners with worldwide leading contract research organization, ICON
- Program targeting the 30% of Major Depressive Disorder related to a dysfunction in the human body’s stress system with a completely novel mode of action
- First patient planned for enrollment in Q1, 2022; first results expected in Q2, 2023
MUNICH, Germany, Sept. 16, 2021 (GLOBE NEWSWIRE) -- HMNC Brain Health, (“HMNC” or the “company”), a clinical stage biopharma company pioneering the development of personalized therapies powered by predictive companion diagnostics, has entered a definitive agreement to initiate a clinical phase II proof-of-concept program for its Nelivabon Project, targeting the 30% of Major Depressive Disorder (MDD) related to a dysfunction in the human body’s stress system with a completely novel mode of action.
This is the first time ever that large-scale precision therapy studies are being conducted in the area of mental health. HMNC Brain Health has developed the compound BH-200, which specifically targets the dysfunction of the HPA-Axis (Hypothalamus‐pituitary‐adrenal axis), also called the stress axis in correlation with a companion biomarker test. The phase II program includes novel features as it in parallel will evaluate the test performance and the activity of BH-200 in two separate studies. A successful program would bring the total of positive trials to three and mark a huge step towards market approval. The Phase II studies will be set up and operated by ICON, one of the world’s leading contract research organizations and will start in Q1, 2022.
“Genetic tests in combination with treatment are a common protocol in other medical areas such as oncology, but it’s a novelty in psychiatry. The ability to apply this combined concept in depression therapy has the potential to be a significant breakthrough in the treatment of mental health disorders,” said Dr. Hans Eriksson, Chief Clinical Development Officer of HMNC Brain Health.
The first patient enrolled for the Nelivabon Project is expected in Q1, 2022 for the first segment of the study, with the second segment of the study slated for Q3, 2022. The initial results data will be available beginning of Q2, 2023.
“As we shift from a traditional ‘one-size-fits-all’ treatment model for mental health disorders, we are exploring more robust, and targeted therapies,” adds Benedikt von Braunmühl, Chief Executive Officer at HMNC Brain Health. “Our Nelivabon Project addresses a high unmet medical need for many patients suffering from a dysfunction in the body’s stress system. Once clinically validated in conjunction with its predictive companion diagnostic, the project will be a potential solution for millions of patients suffering from this form of MDD. We are very confident that our precision psychiatry approach for the treatment of Major Depressive Disorder will prove its noteworthy potential addressing a large patient population.”
About the Nelivabon Project
With the Nelivabon Project, HMNC Brain Health has worldwide exclusive rights to a completely novel compound addressing a high unmet medical need. The project comprises the compound BH-200 and a matching molecular diagnostic test targeting the dysfunction of the HPA-Axis (Hypothalamus‐pituitary‐adrenal axis), also called the stress axis with a completely novel mode of action. The neuropeptide vasopressin coordinates hormonal and behavioral adaptation to stress. Repeated stressors cause an elevated activity of vasopressin in the brain, potentially resulting in an increase of anxiety and a major depressive episode. BH-200 is an antagonist at the vasopressin V1b receptor, expected to be able to target this dysfunction. The clinical development is combined with a predictive companion diagnostic which identifies patients with an underlying dysfunction of the HPA-Axis -related major depressive disorder. These simple to perform molecular-diagnostic tests pave the way for the targeted use of antidepressants as they enable physicians to predict their patient’s response to special treatments. The now starting phase II program includes novel features since it in parallel will evaluate the test performance and the activity of BH-200 in two separate studies. A successful program would bring the total of positive trials to three and mark a huge step towards market approval. The compound BH-200 was in-licensed worldwide exclusively from Sanofi after having demonstrated efficacy despite being tested in an unselected population. At Sanofi, the predefined primary endpoint was met in one of the two MDD studies conducted, supporting the antidepressant efficacy of BH-200. Once clinically validated in conjunction with its predictive companion diagnostic, the Nelivabon Project could represent a highly efficient treatment for those patients suffering stress axis related MDD.
About HMNC Brain Health
HMNC Brain Health (HMNC Holding GmbH) is a clinical stage biopharma company pioneering in developing personalized therapies powered by predictive companion diagnostics, leading to far shorter treatments and higher remission. The company develops a unique pipeline for targeting both major depressive disorder (MDD) and treatment-resistant depression (TRD). HMNC Brain Health is located at one of the leading European biotech hubs in Munich and backed by renowned family offices. The company now enters the next stage of its development with a large-scale licensing and fundraising agenda.
Alexander Schmidt (Europe)
+49 151 22 99 39 765
Anne Donohoe (U.S.)
Investor Contact (U.S.)
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
CrossAmerica Partners LP Maintains Quarterly Distribution21.10.2021 22:20:00 CEST | Press release
• Quarterly distribution of $0.5250 per unit attributable to the third quarter of 2021 Allentown, Oct. 21, 2021 (GLOBE NEWSWIRE) -- CrossAmerica Partners LP Maintains Quarterly Distribution Quarterly distribution of $0.5250per unit attributable to the thirdquarter of 2021 ALLENTOWN, PA (October 21, 2021) – CrossAmerica Partners LP (NYSE: CAPL) announced today that the Board of Directors of its general partner has approved a quarterly distribution of $0.5250 per unit attributable to the third quarter of 2021 (annualized $2.10 per unit). The distribution attributable to the third quarter is payable on November 10, 2021 to all unitholders of record on November 3, 2021. CrossAmerica will host a conference call on November 9th at 9:00 a.m. Eastern Time to discuss second quarter earnings results, which will be released after the market closes on Monday, November 8. About CrossAmerica Partners LP CrossAmerica Partners is a leading wholesale distributor of motor fuels, convenience store operat
Industrivärden avser att kalla till extra bolagsstämma för beslut om indragning av från Handelsbanken erhållna Industrivärdenaktier21.10.2021 20:30:00 CEST | Pressemelding
Industrivärden avser att kalla till en extra bolagsstämma för beslut om minskning av aktiekapitalet genom indragning av de A-aktier i Industrivärden som Industrivärden kommer att erhålla genom extra utdelning från innehavsbolaget Handelsbanken. Åtgärden syftar till att Industrivärdens aktieägare på bästa sätt ska kunna tillgodogöra sig det mottagna värdet. Styrelsens fullständiga förslag kommer att offentliggöras i samband med den kommande kallelsen till en extra bolagsstämma i Industrivärden. Idag beslutade en extra bolagsstämma i Handelsbanken att lämna en extrautdelning till sina aktieägare i form av A-aktier i Industrivärden. Därigenom kommer Industrivärden att erhålla 3.310.769 egna A-aktier, motsvarande ett värde om cirka 930 miljoner kronor. Industrivärdens styrelse har utvärderat olika alternativ för att dess aktieägare ska kunna tillgodogöra sig värdet av mottagna Industrivärdenaktier på bästa sätt. Utifrån dessa överväganden, som bland annat innefattar att Industrivärdens A-a
Industrivärden intends to convene an Extraordinary General Meeting for resolution on cancellation of the Industrivärden shares received from Handelsbanken21.10.2021 20:30:00 CEST | Press release
Industrivärden intends to convene an Extraordinary General Meeting to resolve on a reduction of the share capital by way of cancellation of the Class A shares in Industrivärden that Industrivärden will receive through extra dividend from the portfolio company Handelsbanken. The purpose is to enable the shareholders in Industrivärden to benefit from the received value in the best possible way. The Board of Directors’ complete proposals will be made available in connection with the forthcoming notice to an Extraordinary General Meeting in Industrivärden. An Extraordinary General Meeting in Handelsbanken today resolved on an extra dividend to its shareholders in the form of Class A shares in Industrivärden. Industrivärden will thereby receive 3,310,769 own Class A shares, corresponding to a value of approximately SEK 930 million. The Board of Directors in Industrivärden has evaluated different alternatives in order for its shareholders to benefit from the value of the received Industrivär
Palette Life Sciences tillkännager slutförandet av en finansiering på 30 miljoner dollar och utökning av styrelsen21.10.2021 18:08:47 CEST | Pressemelding
Pengarna ska användas för att utöka kommersiella avtryck i USA och påskynda den kliniska utvecklingen av Barrigel® SANTA BARBARA, KALIFORNIEN och STOCKHOLM, Sverige, Oct. 21, 2021 (GLOBE NEWSWIRE) -- Palette Life Sciences, ett företag med säte i Sverige, som arbetar med att förbättra patientutfall, tillkännagav idag att bolaget har slutfört en finansiering på 30 miljoner dollar i eget kapital under våren och även utökat sin styrelse med fem medlemmar. ”Kapitalanskaffningen gör det möjligt för oss att fortsätta att expandera Palette Life Sciences kommersiella närvaro i USA och på andra viktiga marknader och ta produkter som Barrigel® till den globala marknaden”, säger Per G. Langö, Chief Executive Officer och styrelseledamot för Palette Life Sciences. ”Vi är glada över att stärka vårt team med utnämningen av exceptionella ledare. De kommer att tillföra avsevärd expertis inom sina respektive funktioner medan vi utökar vår produktportfölj och levererar bästa möjliga vård till våra patient
EVS Broadcast Equipment announces stronger 2021 results21.10.2021 17:45:00 CEST | Press release
Publication on October 21, 2021, after market closing Regulated information – Inside information – Press release EVS Broadcast Equipment S.A.: Euronext Brussels (EVS.BR), Bloomberg (EVS BB), Reuters (EVSB.BR) EVS ANNOUNCES STRONGER 2021 RESULTS Based on current projections, the EVS Board of Directors states that the 2021 full year revenue may be higher than the full year revenue guidance of EUR 115 million – EUR 125 million announced on August 24, 2021 within the framework of the first half 2021 results reporting. Therefore, the EVS Board of Directors announces that the 2021 full year revenue guidance is being increased with EUR 5 million and is expected to land between EUR 120 million and EUR 130 million. This revenue increase is based on an accelerated after-Covid catch-up and also on a continuous business recovery in all market pillars. Nevertheless, we remain very concerned about the worldwide shortages in the supply chain. The 3Q21 trading update will be communicated on November 1
Sotheby’s, Creative Artists Agency & NEA’s Connect Ventures Invest in $20 Million Round for Mojito, an NFT Commerce Suite21.10.2021 17:00:00 CEST | Press release
Mojito is out of stealth and aligning with power players in fine art, entertainment and Web3 to bring its customizable commerce suite to market NEW YORK, Oct. 21, 2021 (GLOBE NEWSWIRE) -- Today Mojito, a new NFT commerce suite, announced it has raised $20 million in its first funding round with a valuation of $100 million. With strategic investments from Sotheby’s, the world’s premier destination for art and luxury, and Connect Ventures, an investment partnership between leading entertainment and sports agency Creative Artists Agency (CAA) and global venture capital firm New Enterprise Associates (NEA), Mojito is out of stealth and bringing to market an end-to-end commerce suite for selling digital goods. Future Perfect Ventures led the round with additional participation from Moore Strategic Ventures, CMT Digital, Sfermion, and Ancient. Mojito is the first product to spin out of Serotonin, the premier Web3 marketing firm and venture studio. Demand for digital goods has grown exponenti
JAGGAER Teams Up with Industry Experts for New Procurement with Purpose Webinar Series21.10.2021 16:53:03 CEST | Press release
Panelists from Spend Matters, The Hackett Group, EcoVadis, Harvard University and more share steps for leading environment, social, and governance (ESG) initiatives internally and making a lasting impact RESEARCH TRIANGLE PARK, N.C., Oct. 21, 2021 (GLOBE NEWSWIRE) -- JAGGAER today announces its new ESG-focused webinar series: Procurement with Purpose: Protecting People, the Planet and Profit. The four-part series will provide procurement professionals with valuable and practical insights for driving forward ESG initiatives within their organizations. Attendees will hear from top experts in the space, including analysts from Spend Matters and The Hackett Group and thought leaders from EcoVadis, Harvard University, riskmethods, TealBook and more. “Organizations play a key role in protecting the planet and the rights of people through the way they buy and sell. Procurement is in the prime position to affect change and drive these responsible practices internally,” said Jim Bureau, JAGGAER